This bill asks the FDA to study and report back on how it decides whether biosimilar drugs can be used interchangeably with their original versions. Biosimilars are cheaper copycat versions of expensive biologic drugs (like those used to treat cancer, rheumatoid arthritis, and other serious conditions). When the FDA officially designates a biosimilar as "interchangeable," pharmacists can swap it in for the original drug without needing a new prescription from your doctor—similar to how generic versions of regular medications work. The report would explain what standards the FDA uses to make these decisions, what evidence they look at, and what other factors go into determining interchangeability. This matters to patients because interchangeable biosimilars could make expensive treatments more affordable and accessible, but only if the FDA's approval process is clear and trustworthy. The bill essentially asks for transparency about how these important decisions are being made.

A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable.

Marshall, Roger

 <p>This bill requires the Food and Drug Administration to report on its designation of biosimilars as interchangeable, including the applicable standards, authorities, evidence, and other factors involved in such designations. (Biosimilars that are designated as interchangeable may be substituted for the reference product at a pharmacy without a new prescription, depending on state pharmacy laws.)</p>